BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: Dipeptidyl peptidase 4 inhibitor
Date Journal Article title
2019 Aug BMJ Case Rep DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis.
2019 Aug Biochem Pharmacol Modulation of Sirt1NF-κB interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation.
2019 Aug Clin Transl Sci Odds of Acute Kidney Injury in Patients Receiving Dipeptidyl Peptidase 4 Inhibitors: A National Cohort Study Within the Department of Veterans Affairs.
2019 Aug Cardiovasc Drugs Ther Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
2019 Diabetes Metab Syndr Obes QTQTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the "thorough QTQTc" study (Q-SET study).
2019 Aug Diabetologia The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.
2019 Aug Diabetes Care Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
2019 Aug Life Sci The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
2019 Aug J Comput Biol Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4.
2019 Aug Eur J Drug Metab Pharmaco... DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.
2019 Aug Diabetes Obes Metab Diabetes drugs and stroke risk: intensive vs. conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.
2019 Aug Curr Med Res Opin Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial.
2019 Artif Cells Nanomed Biote... Saxagliptin presses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis.
2019 Jul Diabetes Ther Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program.
2019 Jul Ann Intern Med Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
2019 Jul Int Immunopharmacol CD26 in autoimmune diseases: The other side of "moonlight protein".
2019 Diabetes Metab Syndr Obes GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats.
2019 Jul Diabetes Ther Risk of Fractures Associated with Dipeptidyl Peptidase-4 Inhibitor Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
2019 Jul Materials (Basel) Solid-State Characterization of Different Crystalline Forms of Sitagliptin.
2018 J Assoc Physicians India Effect of Linagliptin on Incretin-axis and Glycaemic Variability in T1DM.
2018 J Assoc Physicians India Teneligliptin: An Economic and Effective DPP-4 Inhibitor for the Management of Type-2 Diabetes Mellitus: A Comparative Study.
2019 Jul Acta Pharmacol Sin Crosstalk between the AktmTORC1 and NF-κB signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs.
2019 Jul Sci Rep Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study.
2019 Jul Diabetes Obes Metab Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
2019 Front Immunol A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
2019 Jul Clin J Gastroenterol Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus.
2019 Jul IUBMB Life Sitagliptin promotes mitochondrial biogenesis in human SH-SY5Y cells by increasing the expression of PGC-1αNRF1TFAM.
2019 Diabetes Res Clin Pract Oral diabetes medication and risk of dementia in elderly patients with type 2 diabetes.
2019 Sep Eur J Pharmacol Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice.
2019 Front Immunol Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
2019 J Pharm Pharmacol Pegfilgrastim and linagliptin potentiate chemoattraction of Ccr2 and Cd44 stem cells accompanied by alterations of cardiac Hgf, Igf-1 and Mcp-1 in daunorubicin cardiomyopathy.
2019 Jul Diabetes Obes Metab Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
2019 Diabetes Ther Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting.
2019 Jun Intern Med Effects of Sitagliptin on the Coronary Flow Reserve, Circulating Endothelial Progenitor Cells and Stromal Cell-derived Factor-1alpha.
2019 Diabetes Metab J Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
2019 Bull Exp Biol Med Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in dbdb Mice.
2019 May - Diabetes Metab Syndr Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy.
2019 Jun Clin Pharmacol Drug Dev Bioequivalence of ErtugliflozinSitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
2019 Am J Transl Res Sitagliptin ameliorates advanced glycation end-product (AGE)-induced degradation of extracellular matrix in human primary chondrocytes.
2019 Jun Australas J Dermatol Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
2019 Diabetes Ther Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
2019 Pharmacol Rep DPP4 inhibitor induces beta cell regeneration and DDR-1 protein expression as an endocrine progenitor cell marker in neonatal STZ-diabetic rats.
2019 Sep - Arch Gerontol Geriatr Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment.
2019 Expert Opin Ther Pat Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
2019 Neuropharmacology DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.
2019 J Diabetes Complications Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes.
2019 Jun Hepatol Res Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
2019 Aug Life Sci Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage.
2019 Apr Can J Diabetes Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
2019 Aug Eur J Pharm Sci Single-dose escalation study of yogliptin in healthy Chinese volunteers.
2019 Diabetes Ther Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin's Effect to Sitagliptin on Cardiac Fat AccumulationFunction in Patients with Type 2 Diabetes.
2019 Jun Diabetes Obes Metab Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
2019 Diabetes Care Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
2019 Jun Clin Ther DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice.
2019 Jun J Eval Clin Pract Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
2019 Diabetes Res Clin Pract Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes.
2019 Expert Opin Drug Saf An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
2019 Acta Endocrinol (Buchar) THE iIN VITROi CYTOTOXICITY, GENOTOXICITY AND OXIDATIVE DAMAGE POTENTIAL OF THE ORAL DIPEPTIDYL PEPTIDASE-4 INHIBITOR, LINAGLIPTIN, ON CULTURED HUMAN MONONUCLEAR BLOOD CELLS.
2019 May Diabetes Obes Metab Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial.
2019 May J Diabetes Investig Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase-4 inhibitors in treatment-naïve patients with type 2 diabetes in Japan.
2019 May J Diabetes Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient.
2019 Diabetol Int Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.
2019 Front Neurol Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke.
2019 Jun Pharmazie Relationship Between Initial Renal Function and the Inhibitory Effect of Dipeptidyl Peptidase-4 Inhibitor Treatment on Renal Function Decline.
2019 J Manag Care Spec Pharm Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
2019 May Int J Mol Sci The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
2019 Exp Gerontol Combined dipeptidyl peptidase-4 inhibitor with low-dose testosterone exerts greater efficacy than monotherapy on improving brain function in orchiectomized obese rats.
2019 Diabetes Res Clin Pract CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.
2019 Am J Manag Care Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
2019 May J Diabetes Investig Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.
2019 Diabetes Care Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting.
2019 May Pharmazie Association between dipeptidyl peptidase-4 inhibitors and autoimmune disorders: Data mining of the spontaneous reporting system in Japan.
2019 May Pharmaceutics Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study.
2019 Am J Transl Res Sitagliptin protects against hypoxiareoxygenation (HR)-induced cardiac microvascular endothelial cell injury.
2019 Drug Metab Dispos Identification of Novel Metabolites of Vildagliptin in Rats: Thiazoline-Containing Thiol Adducts Formed via Cysteine or Glutathione Conjugation.